Benefits of ninerafaxstat in non-obstructive hypertrophic cardiomyopathy

Affiliations

Comment

Gregory B Lim. Nat Rev Cardiol. 2024 Jun.

. 2024 Jun;21(6):357.

doi: 10.1038/s41569-024-01032-y.

No abstract available

Comment on

Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy.
Maron MS, Mahmod M, Abd Samat AH, Choudhury L, Massera D, Phelan DMJ, Cresci S, Martinez MW, Masri A, Abraham TP, Adler E, Wever-Pinzon O, Nagueh SF, Lewis GD, Chamberlin P, Patel J, Yavari A, Dehbi HM, Sarwar R, Raman B, Valkovič L, Neubauer S, Udelson JE, Watkins H. Maron MS, et al. J Am Coll Cardiol. 2024 May 28;83(21):2037-2048. doi: 10.1016/j.jacc.2024.03.387. Epub 2024 Apr 8. J Am Coll Cardiol. 2024. PMID: 38599256 Clinical Trial.

1. Maron, M. S. et al. Safety and efficacy of metabolic modulation with ninerafaxstat in nonobstructive hypertrophic cardiomyopathy: phase 2 study. J. Am. Coll. Cardiol. https://doi.org/10.1016/j.jacc.2024.03.387 (2024) - DOI - PubMed